1stOncology™: Cancer Intelligence Service – Page 12251 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Seattle Genetics to Webcast Virtual Fireside Chat at Needham Healthcare Conference

On April 8, 2020 Seattle Genetics, Inc. (Nasdaq:SGEN) reported that management will participate in a fireside chat at the Needham Healthcare Conference on Tuesday, April 14, 2020 at 12:00 p.m. Eastern Time (Press release, Seattle Genetics, APR 8, 2020, View Source [SID1234556213]). The conference will be held in a virtual meeting format. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

FDA Accepts IND Application for MERKLIN 2 Study

On April 8, 2020 4SC AG (4SC, FSE Prime Standard: VSC) reported that its Investigational New Drug (IND) application for domatinostat in combination with avelumab (Bavencio) has been accepted by the U.S. Food and Drug Administration (FDA) (Press release, 4SC, APR 8, 2020, View Source [SID1234556210]). The MERKLIN 2 study is a Phase II clinical study evaluating domatinostat in combination with avelumab in patients with advanced MCC whose disease has progressed on anti-PD-(L)1 antibody therapy. Avelumab is an anti-PD-L1 antibody co-developed and co-commercialized by Merck KGaA, Darmstadt, Germany and Pfizer.

MCC is a relatively rare, but highly aggressive and immunogenic type of non-melanoma skin cancer. In 2017, avelumab was the first anti-PD-(L)1 antibody approved in both the EU and US for treatment of metastatic MCC. Since 2017, anti-PD-(L)1 antibodies have become the standard of care in metastatic MCC globally. However, a majority of patients may become refractory or relapse on this treatment, and currently do not have access to effective subsequent therapeutic options, which is reflected by a high mortality rate. The MERKLIN 2 study seeks to address this high unmet medical need.

Jason Loveridge, Ph.D., CEO of 4SC: "We are delighted to be working with Merck KGaA, Darmstadt, Germany and Pfizer as pioneers of immune checkpoint blockade to address the high unmet medical need in patients with advanced MCC disease and now that our IND is open, we can go forward with this study in the US as soon as practically possible".

MEI Pharma to Present at the 19th Annual Needham Virtual Healthcare Conference

On April 8, 2020 MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, reported that Daniel P. Gold, Ph.D., president and chief executive officer, will present an overview and business update at the 19th Annual Needham Virtual Healthcare Conference on Tuesday, April 14th at 2:50 PM Eastern Time (Press release, MEI Pharma, APR 8, 2020, View Source [SID1234556206]).

A live audio webcast of the event can be accessed on the Events & Presentations page of the Investors section of MEI Pharma’s website at View Source

An archived replay of the webcast will be available on MEI Pharma’s website for at least 30 days after the live event concludes.

Lilly Confirms Date and Conference Call for First-Quarter 2020 Financial Results Announcement

On April 8, 2020 Eli Lilly and Company (NYSE: LLY) reported that it will announce its first-quarter 2020 financial results on Thursday, April 23, 2020 (Press release, Eli Lilly, APR 8, 2020, View Source [SID1234556204]). Lilly will also conduct a conference call on that day with the investment community and media to further detail the company’s financial performance.

The conference call will begin at 9 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly’s website at View Source A replay will also be available on the website following the conference call.

Immutep’s Partner, EOC Pharma, Continues to Advance Efti in Breast Cancer

On April 8, 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), reported that EOC Pharma ("EOC") and Immutep jointly discussed the current AIPAC results and confirmed plans to continue advancing Efti (designated as EOC202 in China) in metastatic breast cancer (Press release, Immutep, APR 8, 2020, View Source [SID1234556203]).

The confirmation follows EOC Pharma’s analysis of the recently reported Progression Free Survival (PFS) data, including subgroup analysis, from Immutep’s phase IIb AIPAC study.

EOC Pharma is an oncology focused specialty pharmaceutical company headquartered in Shanghai, China, and is the exclusive licensee of efti from Immutep for the Chinese market. Under its agreement with Immutep, it will make further milestone payments to the Immutep if efti achieves specific development milestones as well as undisclosed royalties on sales and is also required to fund the Chinese development of efti.

EOC Pharma CEO, Xiaoming Zou, said: "Our analysis of the overall and subgroup data suggests there is a definite opportunity to progress efti for Chinese patients with metastatic breast cancer. The data allows us to more specifically address certain meaningful patient populations and maximize the chance of a benefit for those patient groups. We also look forward to entering a new phase of collaboration with our partner Immutep."

Immutep CEO, Marc Voigt stated: "We are very pleased about the discussions with EOC Pharma and their perspectives on efti in metastatic breast cancer and we look forward to further developing our collaboration with them."

EOC Pharma, has also confirmed it will continue to advance its ongoing phase I EOC202A1101 study of eftilagimod alpha ("efti" or "IMP321") in metastatic breast cancer in China. The last patient was enrolled and safely dosed in the EOC202A1101 study in February 2020. Data is expected to be reported from EOC202A1101 during 2020, with study completion in Q4 CY2020.

About the EOC202A1101 Trial

The EOC202A1101 study is taking place at the Fudan University Shanghai Cancer Center in China and is a single-center, open label, fixed dose-escalation phase I study in 12 metastatic breast carcinoma patients. The study is evaluating Immutep’s lead product candidate, eftilagimod alpha ("efti" or "IMP321"), in combination with chemotherapy agent, paclitaxel, in Chinese patients. Participants are receiving either 6 mg or 30 mg doses of efti over the six-month treatment period to determine the safety, tolerability and efficacy of the combination treatment, along with the appropriate dose for a potential phase II study. The Chinese IND application for EOC202 (efti) was approved by the Chinese National Medical Products Administration (NMPA) in December 2017.